Michael J. Berendt Ph.d.

Biography

Michael has served as CEO and Chief Scientist of Telesta Therapeutics Inc. and AegeraTherapeutics Inc.  He held Managing Director positions with Research Corporation Technologies and AEA Investors, where he led investments in life sciences companies.  Michael served as Senior Vice President of Research for the Bayer Corporation and a Group Director of Drug Discovery at Pfizer, Inc. During this time he was responsible for managing drug discovery including the Bayer team that discovered Nexavar, a cancer therapeutic.  Michael is a director of Waters Corporation and the NEOMED Institute.  He has served on the board of Alethia, Onyx, Myriad Genetics, and Trillium Therapeutics.  Michael is a graduate of Ohio Dominican College, has a Master’s degree from Miami University, and a Ph.D. in medical microbiology and immunology from Drexel University.  Past awards included grants from the Cancer Research Institute, American Cancer Society, and Leukemia Society of America.

Research Interest

Michael has served as CEO and Chief Scientist of Telesta Therapeutics Inc. and AegeraTherapeutics Inc.  He held Managing Director positions with Research Corporation Technologies and AEA Investors, where he led investments in life sciences companies.  Michael served as Senior Vice President of Research for the Bayer Corporation and a Group Director of Drug Discovery at Pfizer, Inc. During this time he was responsible for managing drug discovery including the Bayer team that discovered Nexavar, a cancer therapeutic.  Michael is a director of Waters Corporation and the NEOMED Institute.  He has served on the board of Alethia, Onyx, Myriad Genetics, and Trillium Therapeutics.  Michael is a graduate of Ohio Dominican College, has a Master’s degree from Miami University, and a Ph.D. in medical microbiology and immunology from Drexel University.  Past awards included grants from the Cancer Research Institute, American Cancer Society, and Leukemia Society of America.